Skip to main content

The RAS Initiative

More than 30 percent of all human cancers – including 95 percent of pancreatic cancers and 45 percent of colorectal cancers — are driven by mutations of the RAS family of genes. NCI established the RAS initiative in 2013 to explore innovative approaches for attacking the proteins encoded by mutant forms of RAS genes and to ultimately create effective, new therapies for RAS-related cancers.

  • The Fourth RAS Initiative Symposium

    This three-day international symposium is the fourth RAS community-wide meeting sponsored by the NCI RAS Initiative. The overarching goal of the NCI RAS Initiative is to mobilize the cancer research community to develop ways to understand and target cancers driven by mutant RAS in an open model of collaboration among government, academic, and industry researchers. The Symposium will feature invited presentations, short presentations from selected abstracts, and poster presentations.

  • RAS Target Identification at FNLCR

    The RAS Initiative is using cutting edge technologies to better define target vulnerabilities in RAS proteins, complexes of RAS proteins with its effector and regulatory partners, cell surface proteins that are enriched in cancer cells driven by mutant RAS, and pathways that are essential to cancer cells but not normal cells.

  • RAS Screens and Assays at FNLCR

    A primary goal of the RAS Initiative at the Frederick National Laboratory for Cancer Research (FNLCR) is to develop assays for RAS activity, localization, and signaling and adapt those assays so they can be used for finding new drug candidates.

  • RAS Central

    To help solve the 30-year challenge of how to treat RAS-driven cancers, we need an open model of collaboration. Whether you are a dedicated RAS expert or curious researcher, we encourage you to help advance the research by joining our RAS community.

  • KRASG12C inhibition drives anti-tumour immunity in lung cancer but combinations with anti-PD1 immunotherapy may only benefit patients with ‘inflamed’ tumours

    Using a novel immunogenic mouse model of KRAS-mutant lung cancer, the Downward lab asks the questions ‘what is the effect of KRAS G12C on the tumour microenvironment and on anti-tumour immunity?’ and ‘how well will anti-PD1 immunotherapy work in combination with KRAS G12C inhibitors?’